Abstract Phenotype-driven approaches in mice are powerful strategies for the discovery of genes and gene functions and for unravelling complex biological mechanisms. Traditional methods for mutation discovery are reliable and robust, but they can also be laborious and time consuming. Recently, high-throughput sequencing (HTS) technologies have revolutionised the process of forward genetics in mice by paving the way to rapid mutation discovery. However, successful application of HTS for mutation discovery relies heavily on the sequencing approach employed and strategies for data analysis. Here we review current HTS applications and resources for mutation discovery and provide an overview of the practical considerations for HTS implementation and data analysis.
Introduction
The sequencing of human, mouse, and other genomes has revolutionised our understanding of mammalian biology, disease, and evolution. Approximately 99 % of human protein-coding genes, and many noncoding RNAs, have an equivalent gene in the mouse genome, making mice an ideal system for modelling human disease (Waterston et al. 2002) . Human genomic variation, including single nucleotide variants (SNVs), inversions, insertions and deletions (INDELs), large chromosomal rearrangements, and copy number variations cause heritable diseases, contribute significantly to the aetiology of complex diseases, and are the basis of personalized medicine (Ng et al. 2012) . Mice that carry equivalent or similar variations can recapitulate key features of human diseases. Variations can be introduced into mice using targeted, reverse genetic approaches (to directly model human disease variation) or at random (induced or spontaneous) to uncover novel disease-causing mutations. The resulting strains of mice provide powerful animal models that can be studied to answer basic biological questions relating to gene function, disease mechanisms, and drug development (Ledford 2012) .
Prior to the advent of genetic engineering and reverse genetic approaches in the 1980s, the primary approach to studying gene function in the mouse was forward genetics, whereby gene discovery followed the observation of a clinical phenotype. The earliest mouse mutants arose spontaneously or were induced by radiation-based strategies at mouse stock centres around the world, like the Medical Research Council Harwell (UK), The Jackson Laboratory (USA), Oak Ridge National Laboratory mouse genetics program (USA), and National Institute of Genetics Mammalian Genetics Laboratory (Japan). Spontaneous mutant mice remain an important tool for the discovery of novel genes, and many spontaneous mutants have become important disease models in a variety of areas, including obesity (Lep ob ) (Zhang et al. 1994) , diabetes (Lepr db ) (Chen et al. 1996) , Duchenne muscular dystrophy (Dmd mdx ) (Sicinski et al. 1989) , and glaucoma (DBA/2J) (John et al. 1998) .
The generation of spontaneous mutants depends on natural mutation rates [which for mice are estimated to be 38 9 10 -9 per base per generation (Lynch 2010) ]. Therefore, large colonies are typically the source of new spontaneous mutant collections. Mutation rates can be significantly increased using mutagenesis. Through the 1940s, radiation was the primary tool for mutagenesis in mice. Later, in the 1980s and 1990s, chemical mutagenesis became more widely used and remains the mutagen of choice for many large-scale mouse mutagenesis programs (Brown and Nolan 1998; Hrabě de Angelis et al. 2000; Nolan et al. 2000; O'Brien and Frankel 2004; Brown and Peters 1996) . Collectively, these programs have generated large collections of mutagenized mice and have developed standardised protocols for phenotyping. Chemical mutagens commonly used include ethylmethanosulfate (EMS) to induce mutations in ES cells and N-ethyl-N-nitrosourea (ENU) to induce single-point mutations randomly in the spermatogonia of male mice, increasing mutation rates to *1 9 10 -6 per base (Concepcion et al. 2004 ). There are now more than 20 ENU mouse mutagenesis programs worldwide (Gondo 2008; Oliver et al. 2007 ) and at least three centres (i.e., The Jackson Laboratory Mutant Mouse Resource, RIKEN BioResource Center, and MRC Harwell) that have large ([10,000) DNA and sperm mouse archives. Induced mutants from these programs continue to provide the critical starting material for high-impact discoveries of novel gene function in the mammalian genome (e.g., Klus et al. 2012; Kurapati et al. 2012; Qian et al. 2011) .
The phenotype-driven approach applied to the discovery of spontaneous or induced mutations is unbiased and is therefore a powerful tool for the discovery of novel genes and novel functions. These mutations provide a full range of alleles, including null (loss of function), hypomorphic (reduced function), and neomorphic (altered function) and therefore are more similar to mutations found in the human genome. Moreover, these mutations can reveal gene functions that would not have been discovered through the analysis of null alleles alone (e.g., Qian et al. 2011) . The offspring of mutagenized mice are subjected to a phenotype screen, which is designed to detect either dominant or recessive phenotypes. Phenotyping can be very broad, is based on clinical phenotypes that are immediately apparent or very specific, and relies on specialised equipment, expertise, or strains (e.g., Blewitt et al. 2005; Kumar et al. 2011; Reinholdt et al. 2004; Shima et al. 2003; Tchekneva et al. 2007) .
When a heritable phenotype is discovered, positional cloning of the underlying mutation follows. Traditionally, this process involves the establishment of linkage between the phenotype and a chromosome, followed by fine mapping. Until recently, fine mapping has required the introduction of a polymorphic strain background, followed by genotyping with genome-wide sets of polymorphic microsatellite DNA markers. Accordingly, the size of the interval depends on the number of recombination events screened and the number of known polymorphic markers within the interval. When the region is small enough to contain a manageable number of candidate genes, each gene is amplified by PCR (usually exon by exon) and individual PCR products are sequenced and analysed for the presence of a putative causative mutation. While this approach to mutation discovery is robust, it can be laborious and time consuming. Moreover, the mapping process is reliant on recombination that is not uniform throughout the genome and can be complicated by phenotypic changes that can result from the introduction of the divergent strain background required for the mapping cross.
Recently, HTS technologies have supplanted fine mapping and sequencing of individual PCR products, drastically changing the process by which mutations are discovered and rapidly accelerating forward genetic approaches. In this review we discuss the impact, application, and challenges of HTS technologies for the discovery of novel mouse mutations.
HTS technologies
Genome sequencing for identification of mutations has, until recently, relied on Sanger sequencing (Sanger et al. 1977) or ''first-generation sequencing.'' In 2005, massively parallel DNA sequencing technologies emerged. These technologies are collectively referred to as ''second-generation sequencing'' or ''high-throughput sequencing'' (HTS) (Margulies et al. 2005; Shendure et al. 2005) . These methods produce millions to billions of reads that are several orders of magnitude faster than traditional methods (Pettersson et al. 2009 ), providing generation of massively parallel sequencing data at unprecedented speed and depth.
Next-generation sequencing technologies have led to a vast increase in the amount of genomic data generated per base coupled with precipitously decreased cost (Metzker 2010) . Currently, HTS technologies can generate a mammalian genome at 209 theoretical coverage for less than $5,000 (USD). HTS sequencing of the mouse genome has been accomplished with a number of commercially available technologies (Arnold et al. 2011; Fairfield et al. 2011; Hilton et al. 2011; Keane et al. 2011; Sun et al. 2012) , including Roche/454 (Margulies et al. 2005) , Illumina/ Solexa (Bentley et al. 2008) , and AB SoLiD (Shendure et al. 2005) (Table 1) . These platforms are based on clonally amplified templates generated from fragments of single DNA molecules and can produce millions of sequence bases (Roche/454 GS FLX) to billions of bases (Illumina HiSeq) in a single sequencing cycle/run (Fedurco et al. 2006; Metzker 2010) . A disadvantage of clonal amplification by PCR is the possible introduction of sequence errors or bias. Hence, ''third-generation sequencing'' (Gupta 2008; Schadt et al. 2010) , i.e., single-molecule sequencing, technologies are being developed to bypass the amplification step. Some examples of third-generation sequencing platforms include those from Pacific Biosciences (Eid et al. 2009 ) and Oxford Nanopore (Maglia et al. 2008) (Table 1) . While these technologies offer improved error rates and, in some cases, very long reads, they are not yet widely used because they are expensive and have relatively low throughput. Another disadvantage of both second-and third-generation sequencing technologies is that both rely on detection of fluorescence at every cycle, which requires storage and processing of large image files. To overcome these limitations, emerging technologies rely on alternative means of signal detection. For example, the Ion Torrent (Rothberg et al. 2011 ) platform detects release of hydrogen ions through an ion sensor. This allows for unprecedented speed at prices that are an order of magnitude lower than secondand third-generation sequencing platforms. However, technologies like the Ion Torrent have yet to achieve the throughput required for routine whole-genome sequencing of the mouse genome.
HTS approaches for mutation discovery
There are a variety of HTS approaches and bioinformatics tools that are potentially useful for mutation discovery in the mouse genome. When determining the best approach, two major considerations need to be taken into account: first, whether to perform targeted, whole-exome, or wholegenome sequencing, and second, which analysis tools are most likely to reveal causative mutations.
Targeted sequencing
Targeted sequencing is the method used to sequence select regions of the genome by either PCR amplification of target genomic regions or hybridization of genomic DNA to probes specific for the target genomic regions Okou et al. 2007; Tewhey et al. 2009 ). These methods effectively enrich the genomic region(s) of interest, and produce very high read depth and are often used to sequence select regions across large sample sets. Targeted sequencing bypasses the necessity for large DNA library preparations, costly bioinformatics infrastructure, and extensive downstream analysis. This approach has been used with great success for the identification of mutations in the mouse genome (Boles et al. 2009; D'Ascenzo et al. 2009; Fairfield et al. 2011; Kurapati et al. 2012) . It requires both a known genomic interval and the design and acquisition of custom probes or primers. Therefore, it is most applicable to mutants with significant mapping data or situations where sufficient funds are available to cover the cost of large custom probe pools. As the cost of sequencing continues to drop, the cost/benefit of purchasing custom probe pools must be considered. However, if the same probe pool can be used across multiple mutant samples, targeted sequencing is a highly efficient approach.
Whole-exome sequencing
Exome sequencing is a targeted sequencing strategy where the vast majority of known coding and some noncoding regions of the genome are enriched by hybridization to DNA or RNA probes and the resulting enriched genomic DNA is then sequenced by HTS (Hodges et al. 2007 ). Predesigned probe pools for mouse exome sequencing are commercially available from Roche NimbleGen (RNG) and Agilent (see Resources box in Appendix). The coding gene models and noncoding RNAs used to guide the design of both commercial probe sets are more comprehensive than the mouse CCDS (collaborative consensus coding sequence) gene set (Pruitt et al. 2009 ), which is restricted to proteins that are common between human and mouse. Instead, nonredundant gene models from the Mouse Gene Catalog (Blake et al. 2011), which incorporates gene annotations from CCDS, National Center for Biotechnology Information (NCBI), Ensembl, and The Vertebrate Genome Annotation (VEGA) database were used. While both Roche NimbleGen's and Agilent's commercial designs are based on the Mouse Gene Catalog, there are differences in probe distribution, so a careful comparison of each design is advisable before choosing a platform. Whole-exome sequencing has been shown to provide high coverage of coding sequence, flanking intron sequence (50-100 bp), and to a limited degree, untranslated regions (UTRs). Application of this approach to large mutant collections has resulted in an *40-60 % success rate for putative mutation discovery (Andrews et al. 2012; Boles et al. 2009; Fairfield et al. 2011 ) depending on the type of mutation (spontaneous or ENU) and at a fraction (*1/3) of the cost of whole genome (see below), coupled with significant reduction in storage and computation requirements for analysis. One limitation of this approach is that *5-15 % of regions are inefficiently enriched depending on the platform used (Andrews et al. 2012; Fairfield et al. 2011 ). An additional limitation of this approach is that it is applicable to the discovery of mutations only within the enriched regions. Mutations in poorly or recently annotated coding sequence or in noncoding sequence will not be found. Historical data on noncoding mutations are impacted by discovery bias (because these mutations have been harder to find and to prove) and, to date, relatively few known causative mutations affect noncoding sequence. However, increasing application of next-generation sequencing approaches to mutation discovery have revealed that a significant percentage of ENU-induced mutations reside in UTRs, but the impact (or causality) of these mutations remains unclear (Boles et al. 2009 ). Noncoding sequences that will not be assessed by exome sequencing include much of the UTRs, many noncoding RNA genes, and regulatory sequences such as transcription factor binding sites and enhancers (Semina et al. 2000; Zuniga et al. 2004; Boles et al. 2009 ). However, these noncoding functional elements often reside in regions of the genome that are conserved between species. Therefore, the limitations of exome sequencing could be overcome if an additional set of probe pools, designed to the noncoding conserved elements [e.g., predicted by Phast (Hubisz et al. 2011)] , was included in the selection. To this end, custom-designed probe pools are commercially available and can be used to augment exome probe pools (see Resources box in ''Appendix'').
Whole-genome sequencing
The clear advantage of whole-genome sequencing is that all regions of the genome are sequenced. In theory, any mutation, including copy number variations and chromosomal rearrangements such as inversions and translocations, could be detected by this approach. However, mutation discovery by whole-genome sequencing can be limited by budget constraints, access to data analysis tools, and data management infrastructure. One important consideration when implementing whole-genome sequencing is coverage. The current cost of generating sufficient sequence to cover the mouse genome at 209 theoretical coverage is $3,000-$4,000 (USD) for 2 9 100-bp sequencing using the Illumina HiSeq platform. This number can certainly vary depending on the sequencing facility and the sequencing platform employed. Whether 209 theoretical coverage provides sufficient minimum read depth for mutation detection depends on a number of factors, including analysis approach (reference-based mapping or de novo assembly), the genotype of the sequenced sample, and the type of mutation (SNV/INDEL or structural variant). For reference-based mapping (discussed below), sequence depth of just five reads coverage over a given nucleotide is considered sufficient read depth to confidently call homozygous variants, and this minimum read depth is usually obtained (for those regions that are accessible to HTS and standard reference-based alignment) with 20-309 wholegenome coverage (Keane et al. 2011 ). However, a read depth of 15 reads is often preferable to call heterozygous variants, especially in cases where the underlying mutation itself introduces allelic bias in the alignment data (e.g., a small deletion that may interfere with mapping of reads from the mutant allele); therefore, higher coverage is desirable. Finally, the data storage and computation requirements for whole-genome sequencing are significant and often underestimated; therefore, the availability of data management and analysis resources must be assessed.
Transcriptome sequencing An alternative exome-based approach is transcriptome analysis (commonly referred to as RNA-seq). In this case, cDNA generated from RNA from a tissue of interest is sequenced. The advantage of this approach is that mutations that cause a change in transcript abundance or that create novel splice variants can be captured. When these mutations occur in expressed genes, they can be identified using the same analysis approaches that are applied to exome data sets. However, when these mutations reside in unexpressed regulatory regions or introns, they will not be represented in the transcriptome data and will require subsequent DNA sequencing for discovery. However, since candidate-affected genes are revealed by the transcriptome data, analysis is vastly simplified. The applicability of RNA-seq can be limited by the availability and/or appropriate selection of tissue. Also, a mutation in one gene can change the expression levels of many other genes in the affected tissue, confounding the mutation discovery process.
Analysis of HTS data for mutation discovery
Identifying variations from next-generation sequence data is challenging and a single, versatile method has not yet been defined. Many different approaches are possible, each with its own strengths and weaknesses. The development of HTS analysis tools is a fast-evolving field and a comprehensive review would be quickly out of date. Therefore, we summarize here the general steps taken for mutation detection analysis, highlighting some of the well-established tools for mutation discovery by HTS (Table 1) . Sequence analysis to discover mutations requires three basic steps: (1) alignment to a reference genome, (2) variant prediction, and (3) variant annotation. Currently, tools are optimized for detecting SNVs and smaller INDELs. Accurate prediction of larger insertions and deletions, other structural variations, and copy number variation is more challenging and is discussed as a separate section.
Alignment
Raw sequence data are usually made available in preformatted, text-based FASTQ files that contain the sequence information organized by individual reads along with quality scores. After ensuring that the sequence is of high quality and has sufficient coverage, the raw sequences (either single end but more commonly paired end) are aligned to a reference genome. The current reference genome for mouse is of C57BL/6J (B6) origin (current build NCBI37, mm9); however, a new assembly of the mouse reference genome (mm10) will soon be available from UCSC Genome Bioinformatics (see Resources box in Appendix). Due to natural genetic drift between mouse colonies, it is not uncommon to find variations when comparing a sequence from a B6 mouse from one colony to the B6 reference genome. When sequencing mutations on non-B6 genetic backgrounds, detection of the causative mutation(s) becomes more challenging because large numbers of strain-specific variations are identified in addition to the phenotype-causing mutations. Strategies that can be used to discern strain-specific variations from putative causative mutations are discussed below.
The challenge with aligning short sequence reads to a reference genome is ''accuracy'' versus ''compute time/ power.'' It is possible to very accurately align sequences to the reference genome but optimal accuracy is slow and computationally intensive. Therefore, compromises are made to ensure alignments are completed in a reasonable time. A wide variety of commercial or publically available alignment tools are available (Table 2) . Historically, aligners such as Maq (Li et al. 2008a ) and ELAND (A. Cox, ELAND: Efficient Local Alignment of Nucleotide Data, unpublished) were the first to lead the field but have been superseded by more accurate aligners such as BWA and Bowtie (Li and Durbin 2010) .
For mutation detection, optimum alignment parameters are required to ensure sufficient genome coverage, maximize placement of uniquely mappable reads, and reduced misplaced reads. Alignment parameters are often set as defaults for the publicly available aligners and should be altered only for specific purposes by experienced users. Importantly, the quality and number of predicted variants will change depending on the quality and parameter settings of the alignment algorithm. This is particularly true for INDELs, where false-negative rates can be relatively high (Keane et al. 2011) . In some cases, it may be useful to run more than one alignment tool to take advantage of the strengths found in different tools. For instance, one strategy is to run BWA to efficiently align the majority of sequence reads to the reference genome and subsequently align the resulting unmapped reads using a slower but more accurate aligner such as Novoalign (http://www.novocraft.com/ main/index.php). Also, as targeted sequencing and exome sequencing have DNA amplification (PCR) steps prior to sequencing, it is necessary to remove PCR duplicates as PCR-induced errors can introduce false positives.
SNVs and INDEL prediction
Once alignments are generated, putative variants are called using a variant caller or assembler (Table 2) . Variant callers will initially predict thousands of SNVs and INDELs and false positives are abundant due to sequencing errors (Nielsen et al. 2011) , low read depth, and/or alignment errors. Filtering strategies are employed to minimize aberrant variant calls. First, variant quality scores are generated and variants that fall below a quality threshold, generally \20-30 (Phred scale), are discarded. Second, variants that are predicted in regions covered by less than a predetermined number of reads are also discarded. Acceptable read depth varies between different projects and users. For example, for homozygous variants, read depth as low as three to six reads is considered acceptable, and for heterozygous variants it may be between 6 and 15 reads. Third, strand bias is taken into account. Genuine variants are expected to occur with equal frequency on forward and reverse strands. In contrast, erroneous variants can show a strand bias. Fourth, some variant callers discard SNVs that are adjacent to INDELs. The remaining highquality variants can then be filtered by allele ratio, depending on the presumed genotype of the sample with respect to the mutation. Homozygous variants are predicted to have allele ratios of 0.7-0.9 or higher and heterozygous variants can have allele ratios of 0.2-0.8, depending on the type of variant and whether it influences read mapping. If a control sample has been sequenced, all common variants between the affected and control samples can be excluded from consideration (unless, of course, the control is heterozygous). Finally, variants can also be filtered based on map position if mapping data are available. SAMtools ) and The Genome Analysis Toolkit (GATK) (DePristo et al. 2011 ) are among the more commonly used variant callers. For SAMtools, ''Pileup/ Filter pileup'' were originally developed, but ''mPileup'' is now the optimum variant caller due to its improvement in predicting INDELs. As the name suggests, GATK is a suite of programs that predicts and annotates variants. Among them, ''Unified Genotyper'' is capable of predicting SNPs and INDELs in individual or multiple samples. As with sequence alignment, prediction of variants using at least two variant callers is an advisable strategy. Many variants will be common to data sets generated by different callers, but each caller is also likely to predict unique variants. Considering only variants predicted by two or more callers is one way to reduce false positives, but it is important to recognize that variants predicted by only one caller need not be false. In addition, standard alignment and SNV/ INDEL calling is not effective for larger structural mutations ([20-30 bp) and these classes of variants are considered separately below.
Annotating and prioritizing variants
Providing functional context for variants allows the potential impact of the variant to be determined and subsequent filtering and prioritization of variants for further testing. Variants are typically annotated based on their position with respect to genes, coding exons, UTRs, splice sites, conserved sequences, repetitive sequence, and their position with respect to known variants. Annotation of known variants can be challenging depending on the strain background involved and the quality of existing variant data. Variant data in dbSNP is one important source of known variant information, with the majority of strain For a more comprehensive review of HTS analysis tools, see Bateman and Quackenbush (2009) variation data coming from large SNP discovery efforts like the Perlegen mouse resequencing/SNP discovery project (Frazer et al. 2007 ) and more recent large-scale wholegenome resequencing efforts like the Mouse Genomes Project at The Sanger Institute, which has resequenced 17 inbred strains and has made available a variation data set of unprecedented scale for the laboratory mouse (Keane et al. 2011) . The 17 inbred strains selected for this project include the progenitors of major inbred laboratory strains and represent four major taxa: M. m. castaneus, M. m. musculus, M. m. domesticus, and Mus spretus. The variation data are available from dbSNP and from The Sanger Institute (http://www.sanger.ac.uk/resources/mouse/genomes/). One limitation of these resources is that they are heavily biased toward a particular set of inbred strains and therefore will not capture all strain and stock/colony-specific variation. Therefore, as mentioned above, sequencing of an unaffected littermate control, while not necessary in all cases, is the ideal way to distinguish between potential mutations and background-specific variation. In addition to the genome build used for reference-based mapping, it is important to consider which databases inform variant annotation. Commonly used high-quality gene models for exon annotation include RefSeq, Ensembl, and Vega. Comprehensive annotation from multiple sources is ideal since not all gene models are in agreement, especially for exons that have little supporting evidence or for UTRs, which are notoriously difficult to annotate. To that end the Mouse Genome Database maintains a curated gene catalogue containing nonredundant gene predictions from RefSeq, Ensembl, and Vega; this gene catalogue is quickly emerging as the gold standard for mouse gene annotation (Blake et al. 2011 ). Additional annotation information includes known and common strain variants (e.g., dbSNP and Sanger Mouse Genomes Project), conserved sequences (e.g., predicted by Phast) (Hubisz et al. 2011) , and repetitive sequences [e.g., RepeatMasker (Jurka et al. 2005) and Tandem Repeats Finder (Benson 1999) ]. For manual annotation, all of the data required for variant annotation are freely available from public genome browsers like UCSC Genome Bioinformatics and Ensembl in file formats that can be directly used for variant annotation.
A variety of tools are available for variant annotation, consequence prediction, and data visualisation (Table 2) , including GATK, Annovar (Wang et al. 2010) , SNPeff (G. Minevich, D. Park, R. J. Poole, O. Hobart, A cloudbased pipeline for analysis of mutant genome sequences, unpublished), Panther cSNP (Thomas et al. 2006) , and NGS-SNP (Grant et al. 2011) . For many tools that predict variant consequences, a probability score is generated reflecting the likelihood that the mutation is deleterious. However, such scores are inconsistent amongst the variation algorithms, suggesting an integrated approach may be required to determine a more reliable prediction. Predicting the potential consequence of the variant allows it to be prioritized for further study based on the predicted impact of the variant. For instance, variants that greatly affect the protein-coding region (e.g., introduction of a stop codon or changing a splice site) may be more likely to be the causative variant than one that is not predicted to change the amino acid (synonymous change). For human mutation detection, additional strategies for prioritising variants are available. For instance, programs such as Polyphen predict the likelihood that a nonsynonymous variant is damaging. Also, assessing conservation (e.g., Genome Evolutionary Rate Profiling, GERP) of the altered nucleotide(s) in mammals/vertebrates can be used as a predictor of consequence. Although these strategies are well established for human mutation detection, mousespecific methods are emerging (Andrews et al. 2012) .
In summary, comprehensive variant calling and annotation provide the means to generate a ''short list'' of the most likely candidate mutations. This heuristic approach involves the application of a series of filters based on the assumption that the causative mutation is most likely to be a unique variant located in a known functional region of the genome, and that its allele ratio reflects the expected genotype of the sample. As a note of caution, due to the flexible nature of the parameters incorporating some of the filtering steps, it is possible to inadvertently remove causative mutations that masquerade as sequencing errors. For example, a heterozygous mutation may be discarded if present at low coverage and/or at low base quality. Similarly, a mutation may be missed if present within a poorly annotated region or in a region of the genome that is inaccessible; regions like this account for 13-23 % of the mouse genome (Keane et al. 2011) . Such discrepancies will be minimised by improvements in the reference sequence, gene annotation, and variant detection methods. Ultimately, any variant data set requires quality control, for example, by assessing false-negative rates using known variants. Furthermore, putative mutations require manual examination, including visualisation of the surrounding alignment using visualization tools (e.g., IGV, Table 1 ) and wet bench validation using independent methods in additional mutant and control samples (if available).
Detection of structural mutations
Unlike SNVs and short INDELs, structural mutations are mutations that involve more than 50 nucleotides (Alkan et al. 2011) . Structural mutations, including duplications, deletions, insertions, inversions, and translocations, frequently underlie mutant phenotypes, especially phenotypes that arise spontaneously or are induced by radiation.
However, spontaneously occurring mutations can arise at any time and in any colony, including ENU colonies (Bannister et al. 2007; Yang et al. 2003) . Therefore, it is important to consider the likelihood of a structural mutation and to apply the appropriate methodological approach. Array-based platforms, including comparative genome hybridization and SNP microarrays, are popular tools for discovery of structural variation. However, these platforms have limited resolution (*2 kb or higher depending on the density of the array) and are not applicable to all types of structural variants. HTS is quickly replacing microarraybased approaches for structural mutation discovery; however, a unified approach for library construction, sequencing, and analysis that will be applicable to all types of structural variants has not yet been identified. Therefore, to fully harness the power of HTS for the discovery of structural mutations, multiple approaches should be considered.
Alternative analysis approaches for discovery of structural variations are accomplished by analysis of read depth or by analysis of read mapping patterns (also known as read pair and split-read approaches). In the former, regions with unusually high or unusually low (or no) coverage are identified using algorithms that count mapped reads and assess read depth with respect to random (or Poisson) distribution . Comparison to control data sets or unrelated data sets of identical size and read length increases the power of this approach. These approaches work well for unbalanced structural variations like duplications and deletions and other CNVs. Structural variations can also cause unexpected or discordant read mapping patterns. In this approach, paired-end sequencing data are essential. Paired-end data can be generated by several methods depending on the desired fragment size. These methods include paired-end mapping (PEM, up to 700 bp), which has been used successfully to discover structural mutations and variations in the mouse genome (Flaherty et al. 2011; Yalcin et al. 2012) , mate-pair approaches (up to 5 kb) (Fullwood et al. 2009; Korbel et al. 2007) , which are ideal for the discovery of inversions and translocations, particularly in genomes that are rich in repetitive sequence, and large insert BAC or fosmid libraries, which are usually confined to experiments requiring de novo assembly.
Individual reads that span the junctions of structural rearrangements also provide critical information for structural mutation discovery. These reads are collectively referred to as ''split reads.'' Successful mapping of split reads depends on the mapping algorithm used, the penalties incurred for suboptimal alignment, and the position of the read with respect to the junction of the structural rearrangement. Therefore, reads that directly map to structural rearrangement breakpoints tend to be underrepresented among mapped reads. To enrich for these rare reads, it is often advantageous to obtain higher coverage by targeted sequencing Sobreira et al. 2011) or by oversampling the whole genome ([309) . Table 2 provides some examples of popular analysis tools for structural variant discovery by HTS. For a more extensive explanation of structural variant discovery approaches by HTS and additional approaches used for discovery of complex structural variation, there are several excellent reviews, including those by Alkan et al. (2011) and Quinlan and Hall (2012) . Now that HTS platforms are evolving towards longer reads, de novo assembly is increasingly possible. According to Gnerre et al. (2011) , genome-wide de novo assembly is possible given read lengths of 100 bp or longer and a combination of paired-end sequences (small fragment sizes, \ 400 bp) and mate-pair libraries with *3 kb of inserts (Earl et al. 2011; Gnerre et al. 2011) . However, for the purpose of discovering structural variants in defined regions (e.g., if a mutation has been mapped to a particular region in or near a gene), local de novo assemblies using paired-end sequencing data are frequently possible without mate-pair libraries. The resulting contigs can then be compared to the reference genome. The advantage of local de novo assembly is that reads containing novel sequence (insertions) or reads that span unique structural rearrangement junctions, which would normally fail to align to reference, are captured in a de novo assembly by virtue of overlapping segments of homology with neighbouring sequences.
Data management and computational resources
Although sequencing costs remain challenging to many laboratories, the so-called $1,000 genome is fast approaching (Schadt et al. 2010) . The bottleneck in using HTS for mutation discovery is data management and processing, which require significant storage and computational infrastructure. On average, a sequencing run can create terabytes of raw sequencing data (generally too large to store) which are usually immediately processed into the more manageable text-based FASTQ files, the deliverable provided by most sequencing cores. Because these files are large, storage of the resultant alignment files, after sequencing reads are mapped to the reference genome, is often preferable. Most alignment tools generate a file in the universal SAM format ) that can then be converted to a compressed binary file, BAM. In fact, this compressed alignment file is emerging as the preferred file format for data storage. The speed with which a BAM file can be generated depends heavily upon the infrastructure available for processing the data. Alignment and assembly can be improved by parallelization, hence many of the modern software packages can now run on multiple processors. Due to the high demand for processing power, future algorithms are implementing new technologies such as highly parallel graphics processing units (GPU) (Klus et al. 2012) .
Many institutions offer bioinformatics support and IT infrastructure for HTS data management and analysis. However, for biologists who do not have access to professional bioinformatics support and who are not familiar with working in the command line interface, there are a growing number of freely and commercially available tools that are designed for management and analysis of HTS data through graphical user interfaces (Table 3) . Galaxy is a popular open, web-based platform that provides access to many of the alignment, assembly, and annotation tools covered in this review (Goecks et al. 2010) . The Galaxy project provides user support and tutorials through Wiki pages, screencasts, and mailing lists. Moreover, Galaxy can be installed locally. However, local implementation of Galaxy and similar software packages does require local IT support and infrastructure, which may not be available at all institutions. Alternatively, cloud infrastructure-based storage and computational resources can be purchased for implementation of HTS analysis tools. Cloud infrastructure is built upon remote servers that are accessible for a fee through the web, providing a means to manage and analyse HTS data that is independent of institutional IT infrastructure. In addition to free, open-source HTS data analysis packages, there are also popular commercial options that rely on either cloud or local storage and computational infrastructure (Table 3 , Fig. 1 ).
Conclusions
Which is the best HTS approach for mutation discovery? The choice of approach depends primarily on the type of mutation(s) to be discovered and the amount of mapping data available, but also on other factors, including budget, the materials available for sequencing, the tools and expertise to analysis the data, and the strain background of the sample used. For ENU-induced mutations, singlenucleotide substitutions (mainly transitions or transversions at A.T base pairs) (Noveroske et al. 2000) in coding sequence or splice acceptor donor sites are the most common lesions, followed by mutations in highly conserved sequences (Boles et al. 2009 ). Therefore, exome sequencing Table 3 is likely to identify phenotype-causing ENU-induced mutations in many cases. However, a complicating factor is that the number of ENU-induced mutations identified will depend on the origin of the sample sequenced. ENU induces approximately 1 mutation per Mb Keays et al. 2006; Quwailid et al. 2004) , and mice from early generations (e.g., G1) will contain more mutations than later generations (e.g., G2 or G3). The higher the number of mutations identified, the greater the burden to identify the phenotype-causing mutation. For spontaneous mutations, larger structural mutations occurring in nonexonic regions (such as introns) are as likely to be causal as SNVs or INDELs. Therefore, sequencing exons, regulatory, and noncoding sequences needs to be considered. This can be achieved by whole-genome sequencing or targeted sequencing. If multiple mutations are likely to be present (as in an ENU-treated genome), the validation burden postsequencing can be high. In this regard, establishing a chromosomal linkage by genetic mapping can be very valuable and is currently easily accomplished using small panels of animals and closely related strain backgrounds (Xia et al. 2010 ). If mapping is not possible, then sequencing a sample from an unaffected but closely related mouse (preferably an unaffected littermate) can reduce validation burden. Caution using this approach needs to be taken if the phenotype of interest is not fully penetrant.
The power of HTS is in closing the gap between mutant phenotype and putative mutation(s). However, final proof of causation for any putative mutation requires significant follow-up biology, often including complementation testing or gene targeting. Implementation of HTS to mutation discovery in the mouse genome has already increased the rate of mutation discovery up to tenfold and unpublished data from the Mutant Mouse Resource, The Jackson Laboratory and MRC Harwell). As analysis tools, sequencing throughput, and accuracy improve, this rate will continue to grow.
Appendix: Resource box

